Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal vs Screening Indicated Aspirin for Preeclampsia Prevention
NCT04797949Phase 4Withdrawn
- Sponsor
- Women & Infants Hospital
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in preeclampsia (2 arms), sponsored by Women & Infants Hospital. Primary endpoint: Adherence to aspirin use up to 42 weeks. Planned start Mar 2021; status: withdrawn.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT04797949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797949.